How can we resolve the complexities of precision medicine to give patients the best chance at beating cancer?
Trapelo knows.
Trapelo is the first, single technology platform used by oncologists, labs and payers that streamlines workflow and facilitates real-time alignment in precision medicine. Trapelo obviates the need for traditional prior authorization, enabling value-based care while quickly giving patients the most appropriate, evidence-supported options when time matters most.
Learn more about what Trapelo knows:
“Implementing precision medicine is no longer just a possibility, it is practically imperative. Cancer patients can’t wait.”
– Michael A. Caligiuri, M.D., President, City of Hope National Medical Center
Listen to the award-winning podcast featuring today's precision medicine innovators.
.jpg)
Featured Guests:
-
Mr. Chet Burrell, formerly CareFirst Blue Cross Blue Shield
-
Dr. Jack West, City of Hope
-
Clynt Taylor, Trapelo Health
-
Luba Greenwood, Google Life Sciences
Listen to the award-winning podcast featuring today's precision medicine innovators.
_SM.png)
Guests include patient advocates, oncologists, educators, entrepreneurs, genomic scientists, pathologists, health plan executives and more including:
-
Lisa Goldman and Tori Tomalia, lung cancer patients and ROS1der founders
-
Dr. John Quackenbush, Harvard School of Public Health
-
Dr. Arturo Loaiza-Bonilla, Cancer Treatment Centers of America
-
Erika Stringer-Reasor, University of Alabama Birmingham
-
Barbara Fortini, PhD, Keck Graduate Institute
-
Dr. Clayton Yates, Tuskegee University
-
Dr. Lee Newcomer, ret. UnitedHealthcare
-
Dr. Windy Dean-Columb, Our Lady of Lourdes Regional Medical Center
-
Dr. Bruce Johnson, Dana Farber Cancer Institute
-
Chet Burrell, formerly CareFirst Blue Cross Blue Shield
-
Dr. Jack West, City of Hope
-
Selin Kurnaz, Massive Bio
-
Clynt Taylor, Trapelo Health
-
Luba Greenwood, Google Life Sciences